Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Consensus Rating of “Moderate Buy” from Analysts
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twenty-four research firms that are covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating […]
14 Sep 09:58 · The Markets Daily